Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin Pharmaceutical (BMRN – Research Report), PTC Therapeutics (PTCT – Research Report) and Teladoc (TDOC – Research Report).
BioMarin Pharmaceutical (BMRN)
In a report issued on April 24, Salveen Richter from Goldman Sachs maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $138.00. The company’s shares closed last Thursday at $82.17.
According to TipRanks.com, Richter is a 5-star analyst with an average return of
Currently, the analyst consensus on BioMarin Pharmaceutical is a Moderate Buy with an average price target of $111.48, representing a 29.2% upside. In a report issued on April 15, Truist Financial also initiated coverage with a Buy rating on the stock with a $140.00 price target.
See today’s best-performing stocks on TipRanks >>
PTC Therapeutics (PTCT)
In a report released today, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics, with a price target of $25.00. The company’s shares closed last Thursday at $25.49.
According to TipRanks.com, Wang is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for PTC Therapeutics with a $29.11 average price target.
Teladoc (TDOC)
Barclays analyst Stephanie Davis maintained a Buy rating on Teladoc today and set a price target of $20.00. The company’s shares closed last Thursday at $13.33, close to its 52-week low of $12.86.
According to TipRanks.com, Davis is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Teladoc with a $19.94 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BMRN:
- BioMarin raises FY24 adjusted EPS view to $2.75-$2.95 from $2.60-$280
- BioMarin reports Q1 non-GAAP EPS 71c, consensus 34c
- BioMarin Reports Record Financial Results for the First Quarter 2024
- BioMarin options imply 5.4% move in share price post-earnings
- BioMarin price target raised to $110 from $100 at Cantor Fitzgerald
